News

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.
Attorney General Jeff Jackson announced that Gilead Sciences will pay $202 million to resolve claims it paid in kickbacks.
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
Galapagos NV (Euronext & NASDAQ: GLPG) today announced its half-year 2025 financial results and provided a second quarter and post-period business update. These results are further detailed in the ...
What Happened? A number of stocks jumped in the afternoon session after a new trade agreement between the United States and ...
Set against the backdrop of the NMA conference, Executive Officers from the National Medical Association, Grammy Award Winning Artist and Advocate Raheem DeVaughn, and Gilead Sciences experts, are ...
DAP Health is presenting “Next Gen Care: Innovations in HIV Prevention,” an event that will highlight cutting-edge care and ...
Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...
The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.
Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...
Several States' Attorneys General reported resolving a case alleging that Gilead Sciences ran an illegal kickback scheme to promote the use of its ...
With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead Sciences, Hookipa Pharma has ...